This report presents the results of the fourth round of the EQA on AST for national public health laboratories on Salmonella (hereafter Salmonella EQA4-AST) within the Food- and Waterborne Diseases and Zoonoses Network (FWD-Net).
These report presents the results of the EQA on antimicrobial susceptibility testing (AST) for national public health laboratories for Campylobacter within the Food‐ and Waterborne Diseases and Zoonoses Network (FWD-Net).
A sizeable proportion of Salmonella and Campylobacter bacteria is still resistant to antibiotics commonly used in humans and animals, as in previous years, says a report released today by the European Centre for Disease Prevention and Control (ECDC) and the European Food Safety Authority (EFSA).
In 2018–2019, data on antimicrobial resistance in zoonotic and indicator bacteria, submitted by 28 EU Member States (MSs), were jointly analysed by the EFSA and the ECDC.
Between May 2018 and December 2020, 193 human cases of Salmonella Enteritidis sequence type (ST)11 were reported in Denmark (2), Finland (4), France (33), Germany (6), Ireland (12), the Netherlands (3), Poland (5), Sweden (6), and the United Kingdom (UK) (122). One in five cases was hospitalised. One death was reported. Fifty percent of the cases were children ≤ 18 years. The most recent case was reported by the UK in December 2020.
The number of reported human cases of illness caused by Campylobacter and Salmonella bacteria across Europe appears to have stabilised over the past five years, according to the latest report on zoonotic diseases by EFSA and ECDC.
This report of the EFSA and ECDC presents the results of zoonoses monitoring activities carried out in 2019 in 36 European countries (28 Member States (MS) and eight non-MS).
This report presents the results of the fourth round of the EQA on antimicrobial susceptibility testing (AST) for national public health laboratories for Campylobacter (Campylobacter EQA4-AST) within the Food‐ and Waterborne Diseases and Zoonoses Network (FWD-Net). The objectives of this EQA4-AST were to determine the accuracy of quantitative AST results reported by participants; to identify common laboratory problems related to the guidance in the EU protocol, and to assess the overall comparability of routinely collected AST data from national public health reference laboratories across Europe.